<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466894</url>
  </required_header>
  <id_info>
    <org_study_id>NASH-Immuron-002</org_study_id>
    <nct_id>NCT01466894</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immuron Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immuron Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection,&#xD;
      multiple dose administration study comprising three groups, with up to 40 patients in each&#xD;
      active treatment and placebo group. Patients with biopsy proven nonalcoholic steatohepatitis&#xD;
      (NASH) and elevated liver enzymes will be randomized to undergo a liver MRI scan and to&#xD;
      receive Imm 124-E or placebo for 24 weeks. During this period, patients will be followed for&#xD;
      clinical and laboratory effects. At the end of 24 weeks of treatment, patients will undergo a&#xD;
      second liver MRI scan. Patients will be followed for an additional 4 weeks for safety after&#xD;
      completion of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor administrative decision&#xD;
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety outcome</measure>
    <time_frame>28 weeks</time_frame>
    <description>No unexpected treatment related SAEs throughout the participation period and the follow up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI liver fat quantitation</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Improvement in MRI fat quantification as determined by a decrease in the fat content by 5% or more from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT levels</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Normalization of alanine aminotransferase levels in patients with NASH from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme improvement</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Improvement in liver enzymes by 20% from baseline from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Improvement in lipid profile by 20% from baseline from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Improvement in HBA1c by 0.5 % from baseline from baseline to week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>IMM 124-E high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM 124-E 3600 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMM 124-E low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM 124-E 1800 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMM 124-E</intervention_name>
    <description>Tablets orally twice a day for 24 weeks</description>
    <arm_group_label>IMM 124-E high dose</arm_group_label>
    <arm_group_label>IMM 124-E low dose</arm_group_label>
    <other_name>Bovine colostrum powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets orally twice daily for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women age 18 to 75 years (inclusive)&#xD;
&#xD;
          -  Subjects with biopsy proven NASH (NAS â‰¥ 4) within one year prior to screening&#xD;
&#xD;
          -  Elevated liver enzymes at screening and at least once within past 6 months (ALT &gt; 30&#xD;
             women, ALT &gt; 40 men)&#xD;
&#xD;
          -  Normal or only slightly impaired synthetic liver function (serum albumin &gt;3.5gm%, INR&#xD;
             0.8-1.5)&#xD;
&#xD;
          -  BMI 18 to 40 (inclusive)&#xD;
&#xD;
          -  Subjects able to adhere to the visit schedule and protocol requirements and be&#xD;
             available to complete the study&#xD;
&#xD;
          -  Women of child bearing potential must be using adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cow milk allergy or lactose intolerance&#xD;
&#xD;
          -  Excessive alcohol use (Women &gt; 20 grams/day, Men &gt; 40 grams/day).&#xD;
&#xD;
          -  Current treatment with Insulin or Incretins&#xD;
&#xD;
          -  Decompensated liver disease&#xD;
&#xD;
          -  Other or concomitant cause of liver disease (viral hepatitis, autoimmune liver&#xD;
             disease, metabolic liver disease, vascular liver disease)&#xD;
&#xD;
          -  Subjects who known to be HIV positive&#xD;
&#xD;
          -  Subjects who have undergone surgery within the last 3 months&#xD;
&#xD;
          -  Subjects who have had a prior gastrointestinal surgery&#xD;
&#xD;
          -  Subjects who have a history of Inflammatory Bowel Disease&#xD;
&#xD;
          -  Subjects who are receiving an elemental diet or parenteral nutrition&#xD;
&#xD;
          -  Subjects with an infectious, immune-mediated or active malignant disease (during the&#xD;
             last 3 months)&#xD;
&#xD;
          -  Subjects with known clinically significant systemic disease&#xD;
&#xD;
          -  Subjects treated with other anti-NASH therapy(s) - thiazolidinediones, vitamin E,&#xD;
             SAM-e, betaine, milk thistle, gemfibrozil, anti-TNF therapies and probiotics) - within&#xD;
             3 months of the liver biopsy&#xD;
&#xD;
          -  Subjects who have been treated with any type of immune modulatory drug, including&#xD;
             systemic steroids or NSAIDs, within the last 3 months&#xD;
&#xD;
          -  Subjects who have received either Immuron, 6-MP, Methotrexate, Cyclosporine, anti-TNF&#xD;
             alpha therapies (Infliximab, Adalimumab, Etanercept) or anti-integrin therapies&#xD;
             (namixilab) within the past 12 months&#xD;
&#xD;
          -  Known history of drug or alcohol abuse, including positive urinary drugs of abuse&#xD;
             screen at the screening visit&#xD;
&#xD;
          -  Subjects who are pregnant as confirmed on screening test&#xD;
&#xD;
          -  Any acute medical situation (e.g. acute infection) within 48 hours of study start that&#xD;
             is considered of significance by the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Fatty liver</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

